Article Details

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer

Retrieved on: 2024-10-22 21:28:06

Tags for this article:

Click the tags to see associated articles and topics

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer. View article details on hiswai:

Excerpt

... Roche Diagnostics, stated in a news release. 1 “Our companion diagnostic for CLDN18 can help identify patients eligible for targeted treatment and ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo